A

Alexion

Global biopharmaceuticals focusing on rare diseases

Epidemiology Intern

Medical ResearchConfirmed live in the last 24 hours
Internship · Summer 2027Boston, MA, USA$41 - $48 /hr

About the Job

Requirements

  • Currently pursuing a PhD or a Master's degree in Epidemiology or a related field.
  • Meet the applicable graduation timeline requirements, with an anticipated graduation date after August 2027.
  • Have U.S. work authorization at the time of application that does not require future sponsorship; OPT support will not be provided.
  • Have graduate-level coursework in epidemiology, including epidemiologic methods, observational research design, biostatistics, or data analysis.
  • Be able to report on site to Boston-Seaport, Massachusetts, three days per week; relocation assistance is not provided.

Responsibilities

  • Contribute to epidemiology and real-world science activities across assigned disease areas, including selected short-term deliverables that advance the broader Epi-RWS strategy.
  • Lead or support the development of descriptive epidemiologic analysis concepts, study plans, protocols, and related project documentation.
  • Conduct structured literature searches and critically appraise epidemiologic publications on selected topics, synthesizing findings into clear evidence summaries.

Desired Qualifications

  • Experience with epidemiologic data analysis and programming languages or tools such as SAS, R, Python, or SQL.
  • Experience conducting literature searches using databases such as PubMed or Embase and critically reviewing epidemiologic research.

About the Company

Alexion

Global biopharmaceuticals focusing on rare diseases

Alexion, now the rare disease group within AstraZeneca, develops and sells therapies for rare and ultra-rare diseases by targeting the complement immune system. Its drugs, such as Soliris and Ultomiris, inhibit the C5 component to slow or stop disease processes, while Strensiq and Kanuma address specific metabolic disorders. It differentiates itself through a deep focus on complement biology, pursuing first- or best-in-class therapies, and using a strategy that blends internal R&D with acquisitions to expand its pipeline. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to a broader international market using AstraZeneca’s scale and capabilities.

Company size
5,001-10,000
Company stage
IPO
Headquarters
Boston, MA
Founded
1992

Recently Posted Jobs

Explore more opportunities at Alexion

See more jobs